Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab

Sponsor: University Hospital, Rouen
Study ID: NCT01299857
Phase: PHASE3
Status: Completed

Conditions

Pemphigus

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Rituximab — DRUG
375mg/m2

Study Details

The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.

Key Dates

Start date: Jun 30, 2011
Status verified: Sep 2012
Primary completion: Jun 30, 2011
Completion: Jun 30, 2012

Study Design

Enrollment: 22 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP

Primary Outcome Measure

Rate of relapse after 5 years of treatment [ Time Frame: five years ]